2017 Year in Review



2017 YEAR IN REVIEW



Education

Increased our collaborative rare disease partnerships to help strengthen our visibility and capacity to serve our patient population, and to increase CCDS knowledge within the medical community and the public, at large.

Continued attendance at national symposiums, conferences and rare disease seminars.

Sponsored the Child Neurology Foundation's Respite Care Notebook, nominated for the Eyeforpharma National Award in Most Valuable Pharma category.



Advocacy

CCDS should be placed on newborn blood screens nationwide for the best outcomes for children. We worked toward the addition of GAMT at the state level in Georgia, Michigan, and New York.

Advocated on the national level by appealing to the Secretary of Health's advisory committee on newborn screening.



Research

Supported approved non-drug research studies for CCDS by promoting volunteer participation in observational studies.

Initiated patient surveys to gather data for global research efforts.

Collaborated with medical professionals, drug developers, local, state and national committees and organizations.



FINANCIALS

OVER \$95,000 RAISED FOR CCDS

General Income

Independent Donations \$21,510 Fundriaing Initiatives \$63,986 Newborn Screening \$10,000 PatientStrong \$455



Rockin' for a Cause


Benefit Concert, Raffle & Auction | Austin, Texas \$50,523 Gross | \$45,531 Net

2017 Walk for Strength

\$7,988. Gross | \$7,276 Net


Suffering for a Cause | Iron-man, Louisville Independent Fundraiser by: Jerry Robinson \$5.475 Net

COMMUNITY ENGAGEMENT



MEASURABLE GROWTH

100% National Increase for CCDS Community Walk to Raise Awareness





182,000





three

Average patients identified monthly

OUR VISION

To help eliminate the challenges for those living with Cerebral Creatine Deficiency Syndromes.

OUR MISSION

To provide patient, family and public education, to advocate for early intervention through newborn screening, and to promote and fund medical research for treatments and cures for Cerebral Creatine Deficiency Syndromes.

OUR BOARD

The ACD was founded in 2012 by parents with children diagnosed with a CCDS. The ACD was established to raise awareness and education of CCDS among the medical community, and the general public, and to advocate on the behalf of patients and families living with CCDS.

2017 Executive Directors

Whitnie Strauss

President

Heidi Wallis

Vice President

Kim Tuminello

Director of Advocacy, Co-Founder

Linda Cooper

Director of Special Initiatives, Co-Founder

Melissa Parker

Director of Finance

2017 Scientific Medical Advisory Board (SMAB)

Dr. Nicola Longo, M.D., Ph.D.

Chief Division of Medical Genetics University of Utah Health Care Pediatrics, Medical Genetics

Dr. Bruce Barshop, M.D., Ph.D.

Metabolic and Mitochondrial Medicine Pediatrics, Rady Children's Specialty University of California San Diego.

Dr. Denise Morita, M.D.

Pediatric Neurologist Granger Medical Clinic Riverton, Utah

Dr. Sarah Young, Ph.D.

Assistant Professor Department of Pediatrics - Medical Genetics Duke University School of Medicine North Carolina

Dr. Matthew Skelton, Ph.D.

Assistant Professor, Department of Pediatrics, University of Cincinnati Division of Neurology Cincinnati Children's Hospital

Dr. Andreas Schulze, M.D., Ph.D.

Assistant Professor Department of Pediatrics - Medical Genetics Duke University School of Medicine

Dr. Yiumo Chan, Ph.D.

Preclinical Drug Discovery Consultant

Dr. Sylvia Stockler

Professor of Pediatrics at University of British Columbia Vancouver, British Columbia, Canada

2017

Ambassadors:

Laura Martin Kelly Shedd

Tina Strauss

2017 Volunteer

Representatives:

Beth Robinson Jerry Robinson Jolene Negre Amy Perry

Nathan Vandenberg Celine Wheaton

2017 Blog

Contributors:

Beth Robinson
Jerry Robinson
Amy Perry
Laura Ward
Whitnie Strauss
Janet Grigoratos
Kelly Pass

Nathan Vandenberg Lisa Renhack

Jane Duffy